Clinical trial NCT02260492: Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
Official title: Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Asthma
Lead sponsor: Oriel Therapeutics
Sponsor class: INDUSTRY
First posted: 2014-10-09
Enrollment: 879
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.


Eligibility criteria: Inclusion Criteria:

1. Males and females ≥ 18 years old of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control
2. Subjects with a reliable clinical history of asthma documented at least 12 weeks prior to screening
3. Subjects with a pre-bronchodilator FEV1 of \> 40% and \<85% of the predicted value during the screening visit and on the first day of treatment
4. Subjects who are currently non-smoking and have not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and had \< 10 pack-years of historical use
5. Subjects with \> 15% reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI). Note: This test may be repeated on a different day if the patient fails the first attempt; and if the patient achieves at least 10% reversibility and the Investigator thinks that a second attempt is appropriate
6. Subjects who are able to discontinue their asthma medications (inhaled corticosteroids and long-acting beta agonists) during the run-in period and for the remainder of the study
7. Subjects who are able to replace current short-acting beta agonists (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits)
8. Subjects who are able to continue the following medications without a significant adjustment of dosage, formulation, or dosing interval for the duration of the study, and judged able by the investigator to withhold them for the specified minimum time intervals prior to each clinic visit: short-acting forms of theophylline for 12 hours, twice-a-day controlled release forms of theophylline for 24 hours, once-a-day controlled-release forms of theophylline for 36 hours
9. Subjects who are able to discontinue the following medications for the specified minimum time intervals prior to the run-in period and for the remainder of the study: oral and parenteral corticosteroids for 1 month and oral short-acting beta agonists for 12 hours
10. Subjects who are able and willing to give their written informed consent to participate in the study.

    \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

    Exclusion Criteria:
11. Female Subjects who are pregnant or breastfeeding
12. Subjects who have life-threatening asthma in the last 10 years, as defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnoea; respiratory arrest or hypoxic seizures, asthma-related syncopal episodes(s), or hospitalizations within the past year or during the run-in period
13. Subjects with evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study
14. Subjects with a hypersensitivity to any sympathomimetic drug (e.g. Salmeterol or salbutamol/albuterol) or any inhaled, intranasal or systemic corticosteroid therapy
15. Subjects who are on other medications with the potential to affect the course of asthma or to interact with sympathomimetic amines (e.g. beta blockers, oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors)
16. Subjects with a viral or bacterial upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit or during the run-in period
17. Subjects with any factors (e.g. infirmity, disability, or geographic location) that the investigator feel would likely limit the patient's compliance with the study protocol or scheduled clinic visits
18. Subjects who have used any investigational drug in any clinical trial within 1 month of receiving the first dose of OT329 Solis™ study medication
19. Subjects who cannot communicate reliably or who are unlikely to co-operate with the requirements of the study, in the opinion of the Investigator
20. Subjects with a milk protein allergy

Primary outcomes:
measure: Area Under the Serial FEV1-time Curve (AUC 0-12h)
timeFrame: 0-12 hours after dosing on Day 1
measure: FEV1 Trough
timeFrame: Post-4 weeks of treatment
Secondary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: From Screen (Day -28) until 1 week post last treatment
Other outcomes:
Locations:
city: Goodyear
country: United States
facility: Oriel Investigative Site
state: Arizona
city: Tempe
country: United States
facility: Oriel Investigative Site
state: Arizona
city: Anaheim
country: United States
facility: Oriel Investigative Site
state: California
city: Los Angeles
country: United States
facility: Oriel Investigative Site
state: California
city: Los Angeles
country: United States
facility: Oriel Invetigative Site
state: California
city: Mission Viejo
country: United States
facility: Oriel Investigative Site
state: California
city: Centennial
country: United States
facility: Oriel Investigative Site
state: Colorado
city: Clearwater
country: United States
facility: Oriel Investigative Site
state: Florida
city: Coral Gables
country: United States
facility: Oriel Investigative Site
state: Florida
city: Homestead
country: United States
facility: Oriel Investigative Site
state: Florida
city: Jupiter
country: United States
facility: Oriel Investigative Site
state: Florida
city: Kissimee
country: United States
facility: Oriel Investigative Site
state: Florida
city: Miami
country: United States
facility: Oriel Investigative Site
state: Florida
city: New Port Richie
country: United States
facility: Oriel Investigative Site
state: Florida
city: Orlando
country: United States
facility: Oriel Investigative Site
state: Florida
city: Tallahassee
country: United States
facility: Oriel Investigative Site
state: Florida
city: Lawrenceville
country: United States
facility: Oriel Investigative Site
state: Georgia
city: Iowa City
country: United States
facility: Oriel Investigative Site
state: Iowa
city: North Dartmouth
country: United States
facility: Oriel Investigative Site
state: Massachusetts
city: Minneapolis
country: United States
facility: Oriel Therapeutics Site
state: Minnesota
city: St. Louis
country: United States
facility: Oriel Investigative Site
state: Missouri
city: Bellevue
country: United States
facility: Oriel Investigative Site
state: Nebraska
city: Omaha
country: United States
facility: Oriel Investigative Site
state: Nebraska
city: Skillman
country: United States
facility: Oriel Investigative Site
state: New Jersey
city: Albuquerque
country: United States
facility: Oriel Investigative Site
state: New Mexico
city: New York
country: United States
facility: Oriel Investigative Site
state: New York
city: Charlotte
country: United States
facility: Oriel Investigative Site
state: North Carolina
city: Raleigh
country: United States
facility: Oriel Investigative Site
state: North Carolina
city: Winston-Salem
country: United States
facility: Oriel Investigative Site
state: North Carolina
city: Cincinnati
country: United States
facility: Oriel Investigative Site
state: Ohio
city: Cincinnati
country: United States
facility: Oriel Investigative Site
state: Ohio
city: Middleburg Heights
country: United States
facility: Oriel Investigative Site
state: Ohio
city: Toledo
country: United States
facility: Oriel Investigative Site
state: Ohio
city: Oklahoma City
country: United States
facility: Oriel Investigative Site
state: Oklahoma
city: Eugene
country: United States
facility: Oriel Investigative Site
state: Oregon
city: Medford
country: United States
facility: Oriel Investigative Site
state: Oregon
city: Portland
country: United States
facility: Oriel Investigative Site
state: Oregon
city: Providence
country: United States
facility: Oriel Investigative Site
state: Rhode Island
city: Warwick
country: United States
facility: Oriel Investigative Site
state: Rhode Island
city: Rock Hill
country: United States
facility: Oriel Investigative Site
state: South Carolina
city: Austin
country: United States
facility: Oriel Investigative Site
state: Texas
city: Austin
country: United States
facility: Oriel Investigative Site
state: Texas
city: Houston
country: United States
facility: Oriel Investigative Site
state: Texas
city: Houston
country: United States
facility: Oriel Investigative Site
state: Texas
city: Plano
country: United States
facility: Oriel Investigative Site
state: Texas
city: Richmond
country: United States
facility: Oriel Investigative Site
state: Virginia
city: Tacoma
country: United States
facility: Oriel Investigative Site
state: Washington
Study officials:
affiliation: Oriel Therapeutics
name: Rick Fuller, MD FRCP
role: STUDY_DIRECTOR
References:
citation: Longphre MV, Getz EB, Fuller R. Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma. Ann Am Thorac Soc. 2017 Feb;14(2):182-189. doi: 10.1513/AnnalsATS.201606-436OC.